Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Frozen Shoulder

Not Applicable

Completed

• Conditions: Pain, Shoulder

• Registration Number: NCT05037994
• Lead Sponsor: Zagazig University

Brief Summary

The patients will be randomly allocated into two equal groups (each 20 patients) using sealed opaque numbered envelopes:

Control Group (C Group) : Patients receive continuous US suprascapular nerve block only.

Gabapentin Group (G Group) : Patients receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.

Both groups compared as regard:

Visual Analogue Scale Range of passive and active movements Patients satisfaction complication related to block The total dose of diclofenac sodium

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-01
• Primary Completion: 2021-09-01
• Study First Submitted: 2021-09-03
• Study First Submitted QC: 2021-09-03
• Study First Posted: 2021-09-08
• Study Completion: 2021-10-30
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-14
• Last Update Posted: 2021-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Body mass index ≥ 18 Kg/m2 ≤ 30Kg/m2
• ASA I, II or III.
• Cooperative patients.

Exclusion Criteria

• local infection at site of injection.
• coagulopathy
• previous history of mental disorders or chronic drug abuse (opioids, tranquilizers)
• known hypersensitivity to any of the drugs used in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Visual analogue scale	6 weeks	10cm line where zero means no pain and ten means worse imaginary pain

Secondary Outcome Measures

Name	Time	Method
Range of passive and active movements	6 weeks	by goniometer
Patients satisfaction	6 weeks	by questionnaire with 3 degrees; 1. Fair; 2. Good; 3. Excellent

Trial Locations

Locations (1)

Amr Shaaban Elshafei; 🇪🇬 Zagazig, Egypt